Related Experiment Video
Updated: Jul 12, 2026

Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
Published on: March 17, 2014
Blastic Plasmacytoid Dendritic Cell Neoplasm in an Adolescent Managed in a Resource-Limited Setting: A Case Report
Garrick Laudin1, Jenifer Vaughan2,3, Sugeshnee Pather3,4
1Department of Clinical Haematology, University of the Witwatersrand, Johannesburg, South Africa, wits.ac.za.
Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare aggressive cancers. This case details a 16-year-old with BPDCN, highlighting diagnostic and treatment challenges in resource-limited settings.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Blastic plasmacytoid dendritic cell neoplasms (BPDCN) are rare, aggressive hematologic malignancies.
- BPDCN are infrequently diagnosed in adolescents and present diagnostic challenges.
Purpose of the Study:
- To report a rare case of BPDCN in a 16-year-old male.
- To highlight diagnostic and therapeutic challenges in resource-limited settings.
Main Methods:
- Case report of a 16-year-old male with BPDCN.
- Diagnostic workup included bone marrow aspirate, flow cytometry, lymph node biopsy, and peripheral blood next-generation sequencing (NGS).
Main Results:
- The patient presented with lymphadenopathy, pancytopenia, and constitutional symptoms.
- Bone marrow aspirate showed 84% blasts; NGS revealed an NRAS p.(G12R) mutation.
- The patient received AML and ALL-type chemotherapy and died from neutropenic sepsis.
Conclusions:
- BPDCN diagnosis and treatment are challenging, especially in adolescents and resource-limited settings.
- The NRAS mutation may play a role in BPDCN pathogenesis.
- Early diagnosis and targeted therapy are crucial for improving outcomes in BPDCN.
More Related Videos
12:58Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023